Glycosylation-inhibiting Factor Uses, Dosage, Side Effects and more
Glycosylation-inhibiting Factor is under investigation in clinical trial NCT02540356 (Phase 1/2a Two-arm Dose-escalation Study of BAX69 in Subjects With Malignant Ascites of Ovarian Cancer).
| Trade Name | Glycosylation-inhibiting Factor |
| Generic | Imalumab |
| Imalumab Other Names | Imalumab, Immunoglobulin g1-kappa, anti-(homo sapiens mif (macrophage migration inhibitory factor, glycosylation-inhibiting factor, glif, gif)), homo sapiens monoclonal antibody |
| Type | |
| Groups | Investigational |
| Therapeutic Class | |
| Manufacturer | |
| Available Country | |
| Last Updated: | January 7, 2025 at 1:49 am |
